ÂÜÀòÂÒÂ×

Michael Arulgnanendran has a diverse work experience spanning a range of industries and roles. Michael is currently working as a Product Manager at Culture Biosciences, a position they have held since June 2023. Prior to this, they had a substantial tenure at Carbon Health, starting in February 2021 and ending in July 2023. At Carbon Health, they held the roles of Product, Billing, and Services, as well as Product Manager for Billing and Services. In these positions, they played a key role in developing Carbon's first audit-able billing system and managing engineering sprints.

Before joining Carbon Health, Michael worked as an Advisor at Stuypend, a mobile payment app for small merchants, from November 2016 to January 2021. Michael also worked at HomeRun IQ as a Product/Customer Development professional from December 2017 to July 2020. In this role, they evaluated market fit for investment products and provided insight into the risk appetite of HOAs for securities.

Additionally, Michael Arulgnanendran has experience as an Investment Advisor at TechnoServe, where they advised micro, small, and medium enterprises in Botswana on available investment products. Michael also worked as a Sales Trader in Equity Derivatives at Citi from July 2015 to February 2017, and at Morgan Stanley from January 2014 to May 2015.

Michael holds an MBA from Cornell University, where they studied from August 2010 to May 2012. Michael also worked as an Engineer in Manufacturing Technology Support at Genzyme from July 2009 to April 2010.

Overall, Michael Arulgnanendran's work experience demonstrates a strong background in product management, billing and services, investment advisory, and sales trading, with experience in healthcare, finance, technology, and biosciences industries.

Michael Arulgnanendran obtained a B.S in Chemical Engineering and Option in Bioengineering from Cornell University, where they studied from 2001 to 2004. Michael later pursued a Master's degree in Business Administration from Cornell University, graduating in 2012.